All In Biotech

Drug Trial Radar · NCT06893016

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight

Last checked: Nov 19, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

640

Planned (sponsor's estimate)

Start

Jun 15, 2025

Primary completion

Jun 15, 2026

Study completion Sep 15, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

Conditions

  • Obesity

Interventions

  • RAY1225Drug

    RAY1225 will be administered SC

  • PlaceboDrug

    Placebo will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body Weight at Week 52Time frame: Baseline and Week 52
  2. Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52Time frame: Baseline and Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.